Skip to content
Clinical Trials – home
HungaryBack to Hungary

Clinical trials in Salgotarjan – page 6

270 clinical trials in Salgotarjan, Hungary. Every trial is listed in the EU Clinical Trials Register and updated daily.

Salgotarjan at a glance
270
clinical trials
  • Research sites0
Type of trial
Recruitment status
Quick filters

270 trials in Salgotarjan

Open in trial search

Schizophrenia

Recruiting

A study testing direclidine compared to placebo in adults with schizophrenia who need hospital care

Investigational
Countries:HungaryHungary
  • Participants:18–64 years · 65+ years
  • Substances:Direclidine
  • Sponsor:Neurocrine Biosciences Inc.

A Study of Brexanolone Caprilcerbate for Adults with Major Depressive Disorder With or Without Anxious Distress

InvestigationalNo placebo
Countries:HungaryHungary
  • Participants:18–64 years · 65+ years
  • Substances:Brexanolone caprilcerbate
  • Sponsor:Seaport Therapeutics Inc.

A Study of fesoterodine and 5-[(1R,5R)-3-Azabicyclo[3.

Investigational
Countries:HungaryHungary
  • Participants:18–64 years · 65+ years
  • Substances:Betovumeline
  • Sponsor:Maplight Therapeutics Inc.

A Study of IMVT-1402 in Adults with Chronic Inflammatory Demyelinating Polyneuropathy to Prevent Disease Relapse

Investigational
Countries:HungaryHungary
  • Participants:18–64 years · 65+ years
  • Substances:Imeroprubart
  • Sponsor:Immunovant Sciences GmbH

Study of divarasib and pembrolizumab compared to standard chemotherapy in previously untreated KRAS G12C-mutated advanced non-small cell lung cancer

Registered drugNo placebo
Countries:HungaryHungary
  • Participants:18–64 years · 65+ years
  • Substances:Budesonide
  • Sponsor:F. Hoffmann-La Roche AG

Study comparing GSK5764227 and topotecan in adults with relapsed small cell lung cancer

Registered drugNo placebo
Countries:HungaryHungary
  • Participants:18–64 years · 65+ years
  • Substances:GSK5764227
  • Sponsor:Glaxosmithkline Research & Development Limited

Study of THIO and cemiplimab compared to chemotherapy in patients with advanced non-small cell lung cancer who have received two previous treatments

Registered drugNo placebo
Countries:HungaryHungary
  • Participants:18–64 years · 65+ years
  • Substances:Cemiplimab
  • Sponsor:Maia Biotechnology Inc.

Safety and Tolerability Study of NBI-1065845 as Additional Treatment for Adults with Major Depressive Disorder

InvestigationalNo placebo
Countries:HungaryHungary
  • Participants:18–64 years · 65+ years
  • Substances:Osavampator
  • Sponsor:Neurocrine Biosciences Inc.

Evaluating NBI-1065845 as an Additional Treatment for Adults with Major Depressive Disorder Who Are Not Responding Adequately to Current Therapy

Investigational
Countries:HungaryHungary
  • Participants:18–64 years · 65+ years
  • Substances:Osavampator
  • Sponsor:Neurocrine Biosciences Inc.

Assessment of NBI-1065845 as an Additional Treatment for Adults with Major Depressive Disorder

Investigational
Countries:BulgariaBulgaria
  • Participants:18–64 years · 65+ years
  • Substances:Osavampator
  • Sponsor:Neurocrine Biosciences Inc.

Study on Ferric Derisomaltose for Patients with Iron Deficiency and Chronic Heart Failure

Registered drugNo placebo
Countries:HungaryHungary
  • Participants:18–64 years · 65+ years
  • Substances:Ferric Derisomaltose
  • Sponsor:Pharmacosmos A/S

Study comparing NVL-655 to alectinib in untreated patients with ALK-positive advanced non-small cell lung cancer

Registered drugNo placebo
Countries:HungaryHungary
  • Participants:18–64 years · 65+ years
  • Substances:NVL-655
  • Sponsor:Nuvalent Inc.

Other cities in Hungary

The busiest research cities in the country

All 73 cities in Hungary

Clinical research in Salgotarjan

What the registry says about research in the country

01 Breast Cancer Research

Innovative clinical trials focusing on hormone receptor-positive and HER2-negative breast cancer treatments, including studies of novel therapeutic combinations and targeted therapies.

  • Advanced metastatic breast cancer treatments
  • Triple-negative breast cancer therapies
  • Hormone therapy resistance studies

Research includes evaluation of new drug combinations and sequential therapy approaches for improved patient outcomes.

02 Lung Cancer Studies

Groundbreaking research on non-small cell lung cancer treatments, particularly focusing on advanced and metastatic cases with specific biomarker profiles.

  • PD-L1 positive NSCLC treatments
  • Combination immunotherapy approaches
  • Stage III unresectable cancer therapies

Studies emphasize personalized treatment approaches based on molecular markers.

03 Head and Neck Cancer

Clinical trials investigating new treatments for head and neck squamous cell carcinoma, including both HPV-negative and recurrent/metastatic cases.

  • Novel combination therapies
  • Immunotherapy applications
  • Treatment for recurrent disease

Research focuses on improving survival rates through innovative therapeutic combinations.

04 Prostate Cancer Innovations

Studies addressing metastatic castration-resistant prostate cancer, evaluating new treatment options and therapeutic combinations.

  • Novel hormonal therapies
  • Treatment-resistant cases
  • Combination therapy approaches

Trials aim to improve outcomes for patients with advanced disease stages.

05 Cardiovascular Research

Studies examining treatments for cardiovascular diseases and related conditions, including stroke prevention and obesity management.

  • Acute ischemic stroke treatments
  • Obesity management in CVD patients
  • Prevention strategies

Research focuses on both therapeutic interventions and preventive approaches.

Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.